Publications by authors named "T Yli-Kerttula"
Article Synopsis
- The study aimed to identify baseline predictors for remission and drug retention in bio-naïve patients with Psoriatic Arthritis (PsA) starting TNF inhibitors, analyzing data from 13 European registries.
- In a pooled cohort of 13,369 patients, results showed that 25% achieved remission and 34% had a moderate response at 6 months, while 63% retained their medication at 12 months.
- Five common baseline predictors, including age, disease duration, sex, CRP levels, and fatigue score, were identified as significant for all three outcomes, suggesting these findings are applicable across different populations.
Article Synopsis
- * It was found that immunization (anti-drug antibodies, or ADAb) affected drug efficacy, with 11% of patients having detectable ADAb, most notably in those using certolizumab pegol.
- * Methotrexate use was shown to reduce the risk of ADAb formation, while low drug trough levels were common and linked to higher disease activity, highlighting the importance of monitoring drug levels in treated patients.
Objective: To evaluate the development of radiological changes of the cervical spine in patients with rheumatoid arthritis (RA) in the NEO-RACo trial treated with an intensive, remission-targeted combination of conventional synthetic disease-modifying antirheumatic drugs (csDMARD) and additional infliximab (IFX) or placebo (PLA) for the first 6 months.
Methods: Ninety-nine patients with early, DMARD-naive RA were treated with a triple combination of csDMARD and prednisolone, and randomized to double-blindly receive either IFX (FIN-RACo+IFX) or PLA (FIN-RACo+PLA) infusions during the first 6 months. After 2 years the treatment strategies became unrestricted, but the treatment goal was strict NEO-RACo remission.
Objective: Frequent monitoring of patients with early rheumatoid arthritis (RA) is required for achieving good outcomes. This study was undertaken to investigate the influence of text message (SMS)-enhanced monitoring on early RA outcomes.
Methods: We randomized 166 patients with early, disease-modifying antirheumatic drug-naive RA to receive SMS-enhanced follow-up or routine care.
Objective: The short-term outcomes of remission-targeted treatments of rheumatoid arthritis (RA) are well-established, but the long-term success of such strategies is speculative, as is the role of early add-on biologics. We assessed the 10-year outcomes of patients with early RA treated with initial remission-targeted triple combination of conventional synthetic disease-modifying antirheumatic drugs (csDMARDs), 7.5-mg prednisolone, and additional infliximab (IFX) or placebo infusions.
View Article and Find Full Text PDF